Project Grant HT94252411002
Award Date
11/15/24
Completion Date
11/14/27
Dollars Obligated
$1.5M
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Minneapolis, MN 55455, USA
Similar Awards
The U.S. Department of Defense's Military Medical Research and Development program (CFDA 12.420) has awarded a $1,243,750 Project Grant to the Regents of the University of Minnesota, doing business as the Office of Sponsored Projects Administration, to develop allogeneic, multiplex base-edited, dual-targeted gamma delta CAR-T cell therapies for the treatment of metastatic castration-resistant prostate cancer. This 3-year award, with a project period from Sep 30, 2024 to Sep 29, 2027, will...
This Project Grant award of $154,000.00 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports research conducted by the Regents of the University of Minnesota to develop a dual-targeting G/D CAR-T cell therapy for the treatment of rhabdomyosarcoma. The award period runs from September 1, 2025 to August 31, 2027. The University of Minnesota, a prominent land-grant research institution, will leverage its extensive medical research capabilities to...
This federal Project Grant award of $614,150.00 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports research by the Regents of the University of Minnesota to enhance the long-term persistence of Chimeric Antigen Receptor (CAR)-Natural Killer (NK) cells for treating solid tumors. The award period runs from July 1, 2025 to June 30, 2027. As a prominent land-grant research institution, the University of Minnesota has a strong track record of...
This federal Project Grant award for $1,399,812.00, provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports advanced biomedical research aimed at transforming healthcare for military service members, veterans, and the broader public. The grant is awarded to the Regents of the University of Minnesota to conduct research on outcomes and late effects in pediatric and adolescent germ cell tumor survivors. This funding will enable...
The Regents of the University of Minnesota received a $515,187 Project Grant award from the Defense Health Agency to conduct research titled "Leveraging Reactivation of Tissue-Resident Memory T Cells in the Tumor Microenvironment for Oncolytic Virotherapy." The grant is part of the Military Medical Research and Development program (CFDA 12.420), which supports basic, applied, and advanced biomedical research to transform military and public health care through innovative medical...
The University of Minnesota, through its Office of Sponsored Projects Administration, was awarded a $1,521,386 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to engage the immune system to kill sarcoma through a comparative oncology approach. The 3-year grant, which began on July 15, 2023 and will be completed by July 14, 2026, supports basic, applied, and advanced biomedical research to transform healthcare for service...
This federal Project Grant award from the Department of the Army Medical Command (CFDA 12.420 - Military Medical Research and Development) provides $1,348,041.00 to the Regents of the University of Minnesota to develop a RET-specific proteomic assay from circulating tumor cells in lethal prostate cancer. The award began on Mar 1, 2024 and is scheduled for completion by Feb 28, 2027. This research aims to transform health care for military service members and the general public through innovative...
The federal Project Grant award of $1,059,132 from the Military Medical Research and Development program (CFDA 12.420) of the Defense Health Agency supports advanced biomedical research aimed at transforming healthcare for military service members, veterans, and the public. The award to the Regents of the University of Minnesota will fund a research project titled "NATURAL KILLER CELL-MEDIATED TARGETING OF IGF1R AND IR-A IN HORMONE RECEPTOR-POSITIVE BREAST CANCER" over the period of...
The University of Minnesota has been awarded a $665,335 Project Grant from the U.S. Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420). The grant, awarded on July 1, 2024, will fund research to investigate "Trapping Inhibitory Signals in Synergy with Cytokine Signaling to Maximize NK Cell Immunotherapy in Ovarian Cancer." The project, set to run through June 30, 2028, aims to develop new immunotherapy approaches for treating...
The Regents of the University of Minnesota received a three-year, $616,064 Project Grant from the Department of the Army Medical Command's Military Medical Research and Development program (CFDA 12.420). The grant will fund research into sex differences in childhood leukemia genomics from June 2021 through June 2024. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research with the goals of transforming military and public health care...